Qiagen NV (QGEN) FinancialsQGENFinancialQiagen NV

QIAGEN N.V. (QGEN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumables and Related Revenues, accounting for 90.3% of total sales, equivalent to $445.00M. Another important revenue stream is Instrumentation. Understanding this composition is critical for investors evaluating how QGEN navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, QIAGEN N.V. maintains a gross margin of 62.41%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 23.69%, while the net margin is 13.82%. These profitability ratios, combined with a Return on Equity (ROE) of 11.93%, provide a clear picture of how effectively QGEN converts its operational activities into shareholder value.

In the context of the broader market, QGEN competes directly with industry leaders such as SNN and BRKR. With a market capitalization of $8.90B, it holds a significant position in the sector. When comparing efficiency, QGEN's gross margin of 62.41% stands against SNN's 70.91% and BRKR's 49.65%. Such benchmarking helps identify whether QIAGEN N.V. is trading at a premium or discount relative to its financial performance.

In Q2 2026, Qiagen reported a net income of $103.4 million and a gross margin of 62.41%, showing solid profitability. However, the year-to-date change is -4.60%, indicating a challenging market environment.